Abstract: The present disclosure provides methods and systems for mapping gene and protein expression in a cell (i.e., mapping gene and protein expression within the same cell simultaneously). The present disclosure also provides methods for diagnosing a disease or disorder (e.g., a neurological disorder such as Alzheimer's disease) in a subject. Methods of screening for a candidate agent capable of modulating gene and/or protein expression are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder, such as Alzheimer's disease, in a subject in need thereof. A plurality of oligonucleotide probes, which may be useful for performing the methods described herein, are also described by the present disclosure, as well as kits comprising any of the oligonucleotide probes described herein.

Abstract: The present disclosure provides methods and systems for profiling RNAs being translated in a cell. Also provided by the present disclosure are methods for diagnosing a disease or disorder in a subject based on a profile of the RNAs being translated in a cell, including cells within an intact tissue. Methods of screening for or testing a candidate agent capable of modulating translation of one or more RNAs are also provided by the present disclosure. The present disclosure also provides methods for treating a disease or disorder in a subject in need thereof. Pairs of probes and sets of probes comprising oligonuclcotide portions, which may be useful for performing the methods described herein, are also described by the present disclosure. Additionally, the present disclosure provides kits comprising any of the probes described herein.

Abstract: The present disclosure provides methods for profiling spatiotemporal gene expression, including methods for profiling spatiotemporal gene expression in vivo in a subject. The present disclosure also provides methods for profiling the role of post-transcriptional modification in spatiotemporal gene expression, methods for studying the role of spatiotemporal gene expression in the development or progression of a disease or disorder, methods for screening for an agent capable of modulating spatiotemporal gene expression, methods for diagnosing a disease or disorder in a subject, and methods for treating a disease or disorder in a subject. Oligonucleotide probes useful in the methods described herein are also provided by the present disclosure. The present disclosure also provide kits comprising the oligonucleotide probes disclosed herein. Systems for profiling spatiotemporal gene expression are also provided by the present disclosure.

Abstract: A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (II): or a pharmaceutically acceptable salt thereof; wherein: R1 is halo; X is —(C?O)NR4—; Y is ?and R2, R3, and R4 are each independently H or an unsubstituted alkyl.

Abstract: Disclosed herein is a decontaminant aqueous solution for decontaminating diisocyanate drum, including 20-97 wt % of at least one alcohol or derivative thereof, based on the total weight of decontaminant aqueous solution, and an alkaline source in an amount effective to provide the solution a pH of at least 8. Further disclosed herein is a method for decontaminating diisocyanate residues in an emptied drum with the decontaminant aqueous solution.

Abstract: This document provides methods and materials for treating mammals (e.g., humans) having an autoimmune disease (e.g., a systemic autoimmune disease such as lupus). For example, one or more SCD1 polypeptide inhibitors (e.g., a SSI) can be administered to a mammal having an autoimmune disease (e.g., lupus) to treat the mammal.

Abstract: An electronic device with display characteristics which reduce long-time damage to user's eyes has a verifiable eye protection system. A verified verification information received from user causes the device to acquire surrounding brightness value detect by an illumination sensor and determine whether the brightness value is in a range suggesting too-low or over bright light. The display screen of the electronic device is turned off when the brightness value is within one of certain brightness ranges. A method for such eye protection is also provided.

Abstract: A battery includes a housing which is bendable. The housing includes a number of cells spaced apart from each other within the housing. The housing further includes a current collecting unit arranged within the housing and configured to electrically couple the number of cells together.

Abstract: An electronic device with display characteristics which reduce long-time damage to user's eyes has a verifiable eye protection system. A verified verification information received from user causes the device to acquire surrounding brightness value detect by an illumination sensor and determine whether the brightness value is in a range suggesting too-low or over bright light. The display screen of the electronic device is turned off when the brightness value is within one of certain brightness ranges. A method for such eye protection is also provided.